Introduction {#s1}
============

The example of penicillin-resistant *Streptococcus pneumoniae,* which was first reported in South Africa, in pediatric patients being treated "prophylactically" with antibiotics for serious viral infections, demonstrates the intercalation of different regions of the world, where issues of antibiotic resistance are concerned [@pone.0068024-Jacobs1]. Regarding methicillin-resistant *Staphylococcus aureus* (MRSA), another important Gram-positive pathogen, it first emerged in the 1960s, soon after methicillin was introduced into clinical therapeutics, and by the end of that decade it was responsible for hospital outbreaks in Western Europe, Australia, and the United States [@pone.0068024-Barber1], [@pone.0068024-Jevons1]. In the late 1980s, MRSA outbreaks were noted in Australia among Aboriginal populations without any exposure to hospitals [@pone.0068024-Bennett1], [@pone.0068024-Faoagali1]. In the United States and elsewhere, the rates of community-associated (CA)-MRSA were increasing until 2008. Certain risk factors for infection with CA-MRSA have been identified [@pone.0068024-Fridkin1], [@pone.0068024-Nichol1], [@pone.0068024-Wallin1]. Recent estimates have reported more people going to hospitals with MRSA infections, than acquiring MRSA infections during hospital stay [@pone.0068024-David1], [@pone.0068024-Naimi1], [@pone.0068024-Vandenesch1].

The epidemiologic changes in MRSA over the years have shown that the distinction between CA-MRSA and hospital-acquired (HA)-MRSA is no longer clear [@pone.0068024-Biber1], [@pone.0068024-Peterson1], [@pone.0068024-Sung1]. By 2004, MRSA had exhibited genetic diversity leading to the emergence of 6 major clones of MRSA worldwide; relating to the Staphylococcal Cassette Chromosome SCCmec types I-VI [@pone.0068024-Ito1], [@pone.0068024-Li1], [@pone.0068024-Oliveira1]. These types are spreading even in areas where MRSA did not appear to pose a considerable threat, such as Africa [@pone.0068024-Antri1], [@pone.0068024-JansenvanRensburg1], [@pone.0068024-Makgotlho1]. Particularly in Africa, MRSA clinical isolates have been reported as early as 1978; a hospital outbreak occurred in 1986--1987 at Johannesburg, South Africa, and CA-MRSA infections have been reported since the early 1990s in Zimbabwe [@pone.0068024-Mason1], [@pone.0068024-Park1], [@pone.0068024-Scragg1].

The healthcare systems in Africa as a whole suffer from inadequate financing, shortages in infrastructure, medical equipment and medications, as well as limited supply of adequately trained healthcare professionals (partly related to "brain drain" to developed countries) [@pone.0068024-World1]. The wide spread of communicable diseases, such as HIV, tuberculosis and malaria, as well as the increasing trends in non-communicable diseases, put a particularly high burden onto healthcare systems. These factors, coupled with suboptimal sanitation and water supply facilities, are reflected in the high maternal and neonatal mortality rates and the low life-expectancy estimates.

However, there is diversity in the socioeconomic conditions between individual countries in Africa, which can allow us to assume that the epidemiology of MRSA might also differ in different regions. It has not been well clarified, though, whether MRSA is more prevalent in African countries of low to medium human development index or vice-versa. In this review, we sought to assess the percentage of methicillin-resistance among *S. aureus* isolates in the region of Africa and whether this is associated with the human development index of each country according to the United Nations classification [@pone.0068024-Nations1].

Methods {#s2}
=======

Literature Search {#s2a}
-----------------

PubMed was systematically searched in January 2013. The following combined search term was applied: "(MRSA OR methicillin-resistant Staphylococcus aureus) AND (prevalence OR epidemiology OR surveillance) AND (Africa OR South Africa OR Western Africa OR Southern Africa OR Eastern Africa OR Central Africa OR Northern OR Africa South of the Sahara OR Africa)". In addition, searches were performed in the World Wide Web by applying the following keywords to the Google search engine: "MRSA Africa", "methicillin-resistant Staphylococcus aureus Africa", "MRSA Africa (prevalence OR epidemiology OR surveillance)", or "MRSA Africa resistance". The Centers for Disease Control and Prevention (CDC), the World Health Organization (WHO) network, the African Field Epidemiology Network (AFENET), as well as the bibliographic references of all the included studies were hand-searched to identify additional potentially eligible studies. Articles published in English and French were only evaluated.

Study Selection {#s2b}
---------------

Any article published after 2005, providing data for the percentage of MRSA among *Staphylococcus aureus* isolates collected from patients with different types of infection in Africa were considered eligible for inclusion in this review. Both clinical and microbiological (*in* *vitro*) studies that included isolates collected from patients meeting the afore-mentioned criteria were eligible. Studies reporting on neonates, children or adolescents were also included. Only studies reporting on non-duplicate isolates were included. Case reports and case series reporting on less than 100 *S. aureus* isolates were excluded.

Data Extraction {#s2c}
---------------

The data extracted from each of the included studies consisted of the first author, year of publication, study design, country and period of the study, number of patients and/or isolates of *S. aureus* and the type of the culture specimen and of staphylococcal infection, the percentage of MRSA to the total *S. aureus* isolates, the percentage of the MRSA isolates that were positive for the Panton Valentine Leukocidin (PVL) toxin and the susceptibility of MRSA to the antibiotics tested in each study. The included studies were stratified primarily according to the Human Development Index (HDI) of the country that the study was performed in (defined by the United Nations as very high, high, medium and low HDI) [@pone.0068024-Nations1].

Focus of the Study {#s2d}
------------------

The focus of this review was, primarily, to assess the percentage of MRSA to the total *S. aureus* isolates in Africa, to which we refer to as "the prevalence of MRSA". We also assessed the susceptibility of MRSA to different antibiotics and the percentage of the MRSA isolates that were positive for the PVL toxin. The susceptibility of the studied isolates was interpreted according to the criteria used in each study.

Results {#s3}
=======

The process of identifying the relevant articles for inclusion in this review is depicted graphically in [Figure 1](#pone-0068024-g001){ref-type="fig"}. In total, 263 articles were evaluated. Of these, 241 articles were excluded due to the reasons presented in [Figure 1](#pone-0068024-g001){ref-type="fig"}, thus leaving 22 articles eligible for inclusion. Additionally, 3 more studies were retrieved from Google searches and 7 more studies were identified from hand-searching the bibliographic references of relevant studies. Finally, 32 studies were evaluated in this review [@pone.0068024-Abera1], [@pone.0068024-Adesida1], [@pone.0068024-Amazian1], [@pone.0068024-Antri2], [@pone.0068024-Ashour1], [@pone.0068024-BenAyed1], [@pone.0068024-BenSaida1], [@pone.0068024-Borg1], [@pone.0068024-Breurec1], [@pone.0068024-Brink1], [@pone.0068024-Buzaid1], [@pone.0068024-Elhamzaoui1], [@pone.0068024-Fayomi1], [@pone.0068024-Ghamba1], [@pone.0068024-Ghebremedhin1], [@pone.0068024-Groome1], [@pone.0068024-Mastouri1], [@pone.0068024-Mesrati1], [@pone.0068024-Mshana1], [@pone.0068024-Naik1], [@pone.0068024-Nwankwo1], [@pone.0068024-Perovic1], [@pone.0068024-Randrianirina1], [@pone.0068024-Rebiahi1], [@pone.0068024-Shittu1], [@pone.0068024-Taiwo1], [@pone.0068024-TerryAlli1], [@pone.0068024-Thabet1], [@pone.0068024-Truong1], [@pone.0068024-vanRensburg1], [@pone.0068024-Wood1], [@pone.0068024-Zinzendorf1].

![Graphical presentation of the process of selection of studies for inclusion in this review.](pone.0068024.g001){#pone-0068024-g001}

High Human Development Index Countries {#s3a}
--------------------------------------

The data extracted regarding the prevalence of MRSA in high human development countries in Africa are presented in [Table 1](#pone-0068024-t001){ref-type="table"}. Specifically, relevant to our review data were available for 2 countries, namely Tunisia and Libya. Regarding Tunisia, data derived from 7 studies referring to the period between 2002 and 2007 [@pone.0068024-Amazian1], [@pone.0068024-BenAyed1], [@pone.0068024-BenSaida1], [@pone.0068024-Borg1], [@pone.0068024-Mastouri1], [@pone.0068024-Mesrati1], [@pone.0068024-Thabet1]. The first study was a retrospective one and referred mostly to pus specimens and blood cultures from one hospital during 2002--2003 [@pone.0068024-Mastouri1]. The prevalence of MRSA was 16%. The PVL toxin was found in 2% of MRSA strains, which all exhibited glycopeptide intermediate susceptibility. Two prospective studies referred to the period between 2003 and 2004, and the prevalence of MRSA was similar, 13% and 12%, respectively. The first of these studies was conducted in 2 Tunisian hospitals as part of a multicenter study and assessed several types of clinical specimens, which were mostly isolated from ICU patients. The second of these studies was conducted in a university hospital and collected samples from hospitalized patients and patients attending the dermatology department [@pone.0068024-Amazian1], [@pone.0068024-BenSaida1].

10.1371/journal.pone.0068024.t001

###### Characteristics of the included studies regarding the epidemiology of MRSA in Africa.

![](pone.0068024.t001){#pone-0068024-t001-1}

  Firstauthor,Year                                                                                               Study design;country; period                                                            Number of patientsand/or isolates                                                                              Culture Specimens                                                                                                   Type of infection                                                      Percentage of MRSA among*S. aureus,* n/N (%)            PVL (+)MRSA,n/N (%)
  --------------------------------------------------------------------------------- --------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------- ---------------------------------------
  **High Human Development Index Countries**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  **Mastouri,** **2006** [@pone.0068024-Mastouri1]                                                      Retrospective; Tunisia;June2002--December 2003                                                        620 isolates *S. aureus*                                                    Pus, blood, catheters, urine, pleuritic fluid, tracheal secretions, CSF fluid                                                                             NR                                                                             96/620 (16)                                  2/96 (2)
  **Amazian,** [a](#nt101){ref-type="table-fn"} **2006** [@pone.0068024-Amazian1]                  Prospective MC; Algeria,Tunisia; March2003--January 2004                                               Tunisia: 336 isolates*S. aureus*                                 Blood, subcutaneous,superficial suppurations,respiratory samples,intravascular device,urine, pressure sores                                                              NR                                                                             42/336 (12)                                     NR
  **Ben Saida,** **2005** [@pone.0068024-BenSaida1]                                                     Prospective; Tunisia;September 2003--March 2004                              147 hospitalized or consultingin dermatology pts; 147isolates *S. aureus*                                                                 NR                                                                                                                   NR                                                                             19/147 (13)                                     NR
  **Borg,** [a](#nt101){ref-type="table-fn"} **2007** [@pone.0068024-Borg1]                   Retrospective Tunisia MC,(Algeria, Egypt, MoroccoMC); 2003 to 2005                                          Tunisia: 586 isolates*S. aureus*                                                                                    Blood                                                                                                             Bacteremia                                                                         105/586 (18)                                    NR
  **Ben Ayed,** **2006** [@pone.0068024-BenAyed1]                                                        Prospective; Tunisia;January 2004--June 2005                                                         475 isolates *S. aureus*                                            Cutaneous pus, blood cultures, urine, materials, respiratory tract specimens, fluid punctions                                    Dermatology, surgery, pediatrics,gynecology neonatology clinics, ICU                                            57/475 (12)                                     NR
  **Thabet,** **2008** [@pone.0068024-Thabet1]                                                        Retrospective; Tunisia;January 2005--December 2006                                                      375 isolates *S. aureus*                                                             Blood, urine, respiratoryspecimens, catheters,cutaneous pus                                                                                      NR                                                                             174/375 (46)                                    NR
  **Mesrati,** **2010** [@pone.0068024-Mesrati1]                                                         Prospective; Tunisia;January 2005--July 2007.                         141 pts (two of which wereeach carrying two distinctstrains); 143 *S. aureus* isolates              Pus, blood, fluid aspirates, pulmonary specimens, urine,medical devices, genital specimens                 Cutaneous, deep-seated, abscesses,bacteremia, bone or joint, pleural-pulmonary, genitourinary, device-related         58/143 (41) CA: 22/77 (29) HA: 36/66 (55)     21/58 (36) CA:9/22 (41) HA:12/36 (33)
  **Buzaid,** **2011** [@pone.0068024-Buzaid1]                                                               Retrospective; Libya;April--July 2007                                                            200 *S. aureus* isolates                                        Pus, wound swabs, centralvenous line tips, endotrachealtube tips, blood cultures,urine catheter tips        Skin and soft tissue, surgical wounds,infections after invasive ICU procedures,chronic osteomyelitis, septic arthritis                   62/200 (31)                                     NR
  **Medium Human Development Index**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  **Perovic,** **2006** [@pone.0068024-Perovic1]                                                  Retrospective MC; SouthAfrica; November1999 --October 2002                                              449 pts; 449 isolates*S. aureus*                                                                                    Blood                                                                                                             Bacteremia                                                         105/449 (23) CA: 21/204 (10) HA: 84/245 (34)                    NR
  **Shittu,** **2006** [@pone.0068024-Shittu1]                                       Retrospective 2 phaseMC; South Africa; March--August 2001and October2002--August 2003                                    227 isolates *S. aureus*                                                                       Pus (mostly), sputum, blood, otic fluid                                                                                                NR                                                                             61/227 (27)                                     NR
  **Groome,** **2012** [@pone.0068024-Groome1]                                               Retrospective record review;South Africa; January 2005--December 2006                                                  161 children                                                                                              Blood                                                                                              Community-acquiredbloodstream infections                                                          63/161 (39)                                     NR
  **Brink,** **2007** [@pone.0068024-Brink1]                                                         Prospective MC; South Africa;January 2006--June 2006                                                     629 isolates *S. aureus*                                                                                        Blood                                                                                              Hospitalized pts withCA or HA infection                                                           226/629 (36)                                    NR
  **van** **Rensburg,** **2012** [@pone.0068024-vanRensburg1]                                    Retrospective surveillance;South Africa; July2007 --June 2011                                              13.746 *S. aureus* isolates                                                                                        NR                                                                                                                   NR                                                                           3298/13.746 (24)                                  NR
  **Amazian,** [a](#nt101){ref-type="table-fn"} **2006** [@pone.0068024-Amazian1]                  Prospective MC; Algeria,Tunisia; March2003--January 2004                                               Algeria: 203 isolates*S. aureus*                                Blood, subcutaneous, superficialsuppurations, respiratory samples,intravascular device, urine, pressure sores                                                             NR                                                                             72/203 (35)                                     NR
  **Borg,** [a](#nt101){ref-type="table-fn"} **2007** [@pone.0068024-Borg1]                    Retrospective Algeria, Egypt,Morocco MC (Tunisia MC);2003 to 2005                                       1591 isolates *S. aureus*;Algeria 569                                                                                  Blood                                                                                                             Bacteremia                                                                     Algeria 256/569 (45)                                NR
  **Antri,** **2010** [@pone.0068024-Antri2]                                                    Prospective microbiological;Algeria; April 2006 toDecember 2007                                 221 pts: 84 pts CA, 137 HA;221 isolates *S. aureus*                                                                            NR                                                                        Skin/soft-tissue, bone/joint,bacteremia, pneumonia, ENT or eye,meningitis urinary tract                    99/221 (45) CA: 34/84 (40) HA: 65/137 (47)       CA: 30/84 (36);HA: 49/137 (36)
  **Rebiahi,** **2011** [@pone.0068024-Rebiahi1]                                                           Prospective; Algeria;April 2007--May 2009                                                          287 pts; 220 *S. aureus*                                                                                         Pus                                                                                                           Surgical wounds                                                                       165/220 (75)                                    NR
  **Wood,** **2009** [@pone.0068024-Wood1]                                                                   Cross-sectional; Botswana;2000-- 2007                           Adult, neonates, pediatric pts;582 *S. aureus*; 538 *S. aureus*with known susceptibilities                                                       Blood                                                                                                             Bacteremia                                                                         239/538 (44)                                    NR
  **Truong,** **2011** [@pone.0068024-Truong1]                                                             Retrospective cohort; Botswana;2000--2007                                            857 pediatric and adult pts;857 isolates *S. Aureus*                              Pus, wound sites, eye, ear, throat,vagina, pleural, pericardial,joint fluid, brain abscesses                                                        SSTIs and others not specified                                                               194/857 (23)                                    NR
  **Borg,** [a](#nt101){ref-type="table-fn"} **2007** [@pone.0068024-Borg1]                    Retrospective Algeria, Egypt,Morocco MC (Tunisia MC);2003 to 2005                                       1591 isolates *S. aureus*;Morocco 465                                                                                  Blood                                                                                                             Bacteremia                                                                     Morocco 88/465 (19)                                 NR
  **Elhamzaoui,** **2009** [@pone.0068024-Elhamzaoui1]                                                    Prospective; Morocco; March2006--March 2008                                                         461 isolates *S. aureus*                                                                                 Blood culture, pus                                                                       Abscesses, ulcers, otitis, bacteremia,osteomyelitis, pulmonary infections                                          89/461 (19)                                     NR
  **Ashour,** **2007** [@pone.0068024-Ashour1]                                                                      Prospective; Egypt; NR                                                              Cancer pts; 140 isolates*S. aureus*                                   Urine, sputum, chest tube, bronchoalveolar lavage, pus, blood, throat swabs, and skininfection swabs                         Various infection sites in cancerpatients (hematologic malignanciesand solid tumors)                                    114/140 (82)                                    NR
  **Borg,** [a](#nt101){ref-type="table-fn"} **2007** [@pone.0068024-Borg1]                   Retrospective Algeria, Egypt, Morocco MC (Tunisia MC); 2003 to 2005                                       1591 isolates *S. aureus*;Egypt 557                                                                                   Blood                                                                                                             Bacteremia                                                                      Egypt 290/557 (52)                                 NR

Study refers to more than one countries

MRSA: Methicillin-resistant *S. aureus*; PVL: Panton Valentine Leukocidin; MC: Multicenter; NR: not reported; NE: non evaluable; CA: community-acquired; HA: hospital-acquired; CSF: cerebrospinal fluid; ICU: Intensive Care Unit; ENT; ear, nose and throat; SSTIs: skin and soft tissue infections.

A more representative and clinically relevant study in Tunisia was part of the Antibiotic Resistance Surveillance and Control in the Mediterranean Region (ARMed) project and referred to the period between 2003 and 2005 [@pone.0068024-Borg1]. The prevalence of MRSA among blood cultures in 4 Tunisian hospitals was 18%. In another, prospective study conducted in 1 hospital in 2004--2005, which analyzed mostly samples of cutaneous pus and blood, the prevalence of MRSA was 12% [@pone.0068024-BenAyed1]. In the remaining 2 studies, the one done in 2005--2006 and the other in 2005--2007, each conducted in a single hospital, the prevalence of MRSA rose to 46% and 41%, respectively [@pone.0068024-Mesrati1], [@pone.0068024-Thabet1]. The clinical samples were mostly blood cultures and cutaneous pus in the former study, and cutaneous pus, blood cultures and samples from deep seated infections, in the latter study. Among the 58 (41%) of MRSA isolates from one of the above-mentioned studies, (29%) were community-acquired and (55%) were hospital-acquired. Forty-one percent of the community- acquired isolates and 33% of the hospital-acquired isolates were PVL toxin positive.

One study has reported on the prevalence of MRSA in Libya [@pone.0068024-Buzaid1]. This was a retrospective study, which assessed 200 isolates in a surgical and trauma hospital for a period of 4 months during 2007. The prevalence of MRSA was 31%.

Medium Human Development Index Countries {#s3b}
----------------------------------------

The data extracted regarding the prevalence of MRSA in medium human development countries in Africa are presented in [Table 1](#pone-0068024-t001){ref-type="table"}. Specifically, relevant data to our review were available for 5 countries, namely South Africa, Algeria, Botswana, Morocco and Egypt. All studies included more than 200 patients, except from one study in Egypt that included 140 patients. Regarding South Africa, data derived from 5 studies. The first study was retrospective in nature and assessed 449 bacteremic patients in 1999--2002 in two academic hospitals [@pone.0068024-Perovic1]. The prevalence of MRSA was 23%. Community-acquired MRSA accounted for 20% hospital-acquired MRSA accounted for 80% of the total MRSA isolates. Another retrospective study was conducted in 14 health institutions in 2001--2003 [@pone.0068024-Shittu1]. Pus from wound specimens accounted for most of the clinical samples. The prevalence of MRSA was 27%.

A prospective nationwide study from 12 laboratories of 7 private pathology practices in South Africa was done over a 6-month period in 2006 and assessed blood isolates [@pone.0068024-Brink1]. The prevalence of MRSA was 36%. A retrospective study assessed children with community-acquired bacteremia through 2005--2006 in a setting with high prevalence of HIV infection [@pone.0068024-Groome1]. The prevalence of MRSA in this population was 39%. The most recent study from South Africa was retrospective in nature and referred to a period between 2007 and 2011 [@pone.0068024-vanRensburg1]. A large number of isolates, 13.746 in total, were collected from three tertiary- and two secondary-level public hospitals. The prevalence of MRSA was 24%.

Regarding Algeria, available data derived from four studies. The first study was conducted in 2003--2004 in four hospitals, reported a prevalence of MRSA of 35% [@pone.0068024-Amazian1]. Half of the specimens were collected from subcutaneous punctures, 17% from urine and 11% from blood. One third of the MRSA isolates were collected in maternity units. The second study, which was part of the Antibiotic Resistance Surveillance and Control in the Mediterranean Region (ARMed) project, assessed bacteremic episodes during 2003--2005 in 567 patients, in 23 hospitals [@pone.0068024-Borg1]. The prevalence of MRSA was 45%. The third study, which was conducted in 2006--2007, provided data for community and hospital acquired MRSA, regarding mostly skin and soft tissue infections [@pone.0068024-Antri2]. The prevalence of MRSA was 40% and 47%, respectively, while the prevalence of MRSA among all the isolates was 45%. In the same study the carriage of the PVL toxin was similar (36%) in both community and hospital acquired MRSA. The fourth study, which was conducted in 2007--2009, reported on MRSA isolated from pus in surgical patients in a single hospital [@pone.0068024-Rebiahi1]. The prevalence of MRSA was 75%.

In Botswana, 2 studies were identified as relevant to this review, which both referred to the period between 2000 and 2007 [@pone.0068024-Truong1], [@pone.0068024-Wood1]. In the first study, which included neonates, children and adults, the prevalence of MRSA was 23%. The prevalence of MRSA was 18% specifically for skin and soft tissue infections in patients13--49 years of age, who accounted for almost two thirds of the study population. In the second study, which included neonates, children and adults, the prevalence of MRSA was 44%, and it was higher in neonates and adults than children.

In Morocco, according to 2 included studies, which referred to the period of 2003--2005 and 2006--2008, the prevalence of MRSA was 19% in both studies. The study reporting for 2003--2005 was part of the Antibiotic Resistance Surveillance and Control in the Mediterranean Region (ARMed) project [@pone.0068024-Borg1]. The study included bacteremic patients in 3 Moroccan hospitals that had a capture population of about 4% of the total country population. The second study was conducted during 2006--2008 in two Moroccan teaching hospitals, included patients with bacteremia and pyogenic infections [@pone.0068024-Elhamzaoui1].

Regarding Egypt, we identified two studies as eligible for inclusion in this review [@pone.0068024-Ashour1], [@pone.0068024-Borg1]. The first study, which did not report on the period of collection of the isolates, included cancer patients only, and the prevalence of MRSA was 82% [@pone.0068024-Ashour1]. The second study, referring to 2003--2005, was done in nine hospitals as part of the Antibiotic Resistance Surveillance and Control in the Mediterranean Region (ARMed) project, with a capture population of 17% of the total country population [@pone.0068024-Borg1]. The prevalence of MRSA among *S. aureus* blood cultures was 52%, exhibiting an increasing trend during the 3-year period of the study.

Low Human Development Index Countries {#s3c}
-------------------------------------

The data extracted regarding the prevalence of MRSA in low human development countries in Africa are presented in [Table 2](#pone-0068024-t002){ref-type="table"}. Specifically, 13 studies were evaluated [@pone.0068024-Abera1], [@pone.0068024-Adesida1], [@pone.0068024-Breurec1], [@pone.0068024-Fayomi1], [@pone.0068024-Ghamba1], [@pone.0068024-Ghebremedhin1], [@pone.0068024-Mshana1], [@pone.0068024-Naik1], [@pone.0068024-Nwankwo1], [@pone.0068024-Randrianirina1], [@pone.0068024-Taiwo1], [@pone.0068024-TerryAlli1], [@pone.0068024-Zinzendorf1]. Out of these, 7 referred to Nigeria, and 1 to each of the following countries: Tanzania, Ethiopia, Ivory Coast, Eritrea, and Madagascar. There was also 1 multinational study with data from Madagascar, Cameroon, Senegal and Niger.

10.1371/journal.pone.0068024.t002

###### Characteristics and outcomes of the included studies

![](pone.0068024.t002){#pone-0068024-t002-2}

  First author,Year                                                                    Study design; country; period                                        Number of patients and/or isolates                                                       Culture Specimens                                                                                                              Type of infection                                                                       Percentage ofMRSA among *S. aureus* n/N (%)   PVL (+) MRSA n/N (%)
  ------------------------------------------------------------ ----------------------------------------------------------------------------- ---------------------------------------------------------------- ------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------- -----------------------
  **Low Human Development Index**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  **Adesida, 2005** [@pone.0068024-Nichol1]                                  Retrospective MC; Nigeria; August 1998--June 2002                                   276 isolates*S. aureus*                                     Variety of clinicalmaterials, MRSA:Aspirate, wound,amniotic fluid                                              Invasive infections; MRSA: Recurrent septic arthritis, preterm contraction,chronic osteomyelitis                                                26/276 (9)                             NR
  **Taiwo, 2005** [@pone.0068024-Taiwo1]                                      Retrospective; Nigeria; January--December 2001                                     141 isolates*S. aureus*                                                      SSTIs followingsurgery or trauma                                                                                                             NR                                                                                               45/141 (32)                            NR
  **Ghebremedhin,** **2009** [@pone.0068024-Ghebremedhin1]                          Prospective MC; Nigeria;2006--2007                            1,300 adultand pediatricpts; 346isolates *S.* *aureus*                        Wounds, corneal,conjunctival,auricular, genital,nasal swabs                     Conjunctivitis, cataracts, otitis,pyomyositis, cellulitis, burns, UTI,trauma, fracture, posttraumatic/postsurgical wounds, diabetic foot, skin infections     70/346 (20) HA:37/70 (53) CA:33/70 (47)     33/70 (47)all CA-MRSA
  **Fayomi, 2011** [@pone.0068024-Fayomi1]                                      Prospective; Nigeria;January--December 2009                                      158 isolates*S. aureus*                                 Pus, aspirates,sputum, throatswabs, urine, CSF,vaginal swabs,semen, blood                                                                                         NR                                                                                               49/158 (31)                            NR
  **Nwankwo,** **2011** [@pone.0068024-Nwankwo1]                               Retrospective; Nigeria;January--December 2009                                     150 isolates*S. aureus*                       Wounds, blood,umbilical cord,urine, ENT, abscess,catheter tips, pleuralaspirate and skin swab                                                                               NR                                                                                               16/150 (11)                            NR
  **Terry Alli,** **2012** [@pone.0068024-TerryAlli1]                                  Retrospective MC;Nigeria; NR                                              116 isolates*S. aureus*                                        Wound, eye, ear,urine, endocervical,urine, aspirate andblood                                                                                               NR                                                                                  48/116 (41) CA:3/48 (7) HA:45/48 (93)           28/116(24)
  **Ghamba, 2012** [@pone.0068024-Ghamba1]                                               Prospective; Nigeria; NR                             150 pts; 150isolates *S.* *aureus*; (2healthysubjectsexcluded)          Urine, vaginal,wound, urethral,seminal, sputum,endocervical, earand nasal swabs                                                                                      NR                                                                                 42/148 (28) CA:18/42 (43) HA:24/42 (57)              NR
  **Randrianirina,** **2007** [@pone.0068024-Randrianirina1]              Retrospective; Madagascar; January 2001--December 2005                           574 isolates*S. aureus*; CA506 HA 68                CA: genital tract,pus, urinary tract,respiratory tract HA:surgical wounds,cutaneous pus, blood                                                          Community and hospital acquired infections                                                              36/574 (6) CA:33/506 (7) HA:3/68 (4)                NR
  **Breurec, 2010** [@pone.0068024-Breurec1]                    Prospective; Madagascar, Niger, Senegal, Cameroon; January 2007--March 2008                      542 isolates*S. aureus*                                                   Pus, blood, urine,pulmonary secretions                                                   SSTIs, surgical wounds, bacteremia/septicemia, urinary/genital tract,osteomyelitis/myositis, pulmonaryinfections                                        86/542 (16)                    17/86 (20)(13/17HA)
  **Abera, 2008** [@pone.0068024-Abera1]                                  Prospective cross sectional; Ethiopia; April--June 2006                      151 inpts, 70outpts; 162isolates*S. aureus*                                            Surgical wound,ENT swabs, urine                                                                                                              NR                                                                                               89/162 (55)                            NR
  **Zinzendorf,** **2008** [@pone.0068024-Zinzendorf1]                               Retrospective MC; IvoryCoast; NR                                Adults andpediatric pts;180 isolates*S. aureus*                                                         NR                                                                                                                            NR                                                                                               70/180 (39)                            NR
  **Mshana, 2009** [@pone.0068024-Mshana1]                                        Prospective; Tanzania.;April--July 2008                                        160 isolates*S. aureus*                                                       Pus, wound swabsand aspirates                                                                                                               NR                                                                                               26/160 (16)                            NR
  **Naik, 2009** [@pone.0068024-Naik1]                                                  Retrospective; Eritrea; NR                                               278 isolates*S. aureus*                                                             Pus, ear discharge                                                                                                                    NR                                                                                               26/278 (9)                             NR

a: Study refers to more than one countries.

MRSA: Methicillin-resistant *S. aureus*; PVL: Panton Valentine Leukocidin; MC: Multicenter; NR: not reported; NE: non evaluable; CA: community-acquired; HA: hospital-acquired; SSTIs: skin and soft tissue infections; UTI: urinary tract infection; CSF: cerebrospinal fluid; ENT; ear, nose and throat.

In Nigeria, one study was conducted in 10 hospitals in the north-central part during 1998--2002, and reported a prevalence of MRSA of 9% [@pone.0068024-Adesida1]. Samples were collected from several clinical sites and infections. In another study, referring to 2002 for the south-west part of the study, the prevalence of MRSA was 32% [@pone.0068024-Taiwo1]. Samples were collected from patients with skin and soft tissue infections and infections following surgery and trauma. Another study was conducted during 2006--2007 in 2 hospitals in the south-west part of the country, assessing mostly wound samples from adult, pediatric, and neonatology patients [@pone.0068024-Ghebremedhin1]. The prevalence of MRSA was 20%. Forty-seven percent and 53% of the isolates were community-and hospital-acquired, respectively. For community-acquired isolates, otitis, conjunctivitis and skin infections were the commonest infections.

In a retrospective study, conducted during 2009 in the northwest part of Nigeria, including several clinical specimens, the prevalence of MRSA was 11% [@pone.0068024-Nwankwo1]. In a prospective study, which was conducted also in 2009, in the south-west part of Nigeria, and assessed *S. aureus* isolates from various types of clinical specimens, the prevalence of MRSA was 31% [@pone.0068024-Fayomi1]. Another study in the south-west part of Nigeria, which did not mention the exact study period, reported a prevalence of MRSA of 41% for among several types of samples [@pone.0068024-TerryAlli1]. Most of these MRSA isolates (93%) were hospital-acquired. The PVL toxin was detected in 24% of the MRSA isolates. Finally, a study conducted in the north-eastern part of the country, which did not mention the study period, reported a prevalence of MRSA of 28% for various clinical specimens, with 43% of MRSA originating from outpatients and 57% from inpatients [@pone.0068024-Ghamba1].

A retrospective study from Madagascar reported on a 4-year period (2001--2005) [@pone.0068024-Randrianirina1]. Most of the analyzed isolates were community-acquired (88%) and originated from genital and urinary specimens and pus. The overall prevalence of MRSA was 6%, while for the community- and hospital-acquired infections the prevalence of MRSA was 7% and 4%, respectively. In the prospective multinational study from Madagascar, Senegal, Cameroon and Niger, which was performed during 2007--2008, the prevalence of MRSA among specimens collected from skin and soft tissue infections (SSTIs) and surgical site infections was 16% [@pone.0068024-Breurec1]. The PVL toxin was positive in 20% of isolates, of which 76% were hospital-acquired.

A prospective study from a teaching hospital in Tanzania, which serves 13 million people, reported a prevalence of MRSA of 16% for a 4-month period in 2008 [@pone.0068024-Mshana1]. Specimens were mostly collected from surgical patients. A prospective study in both outpatients and inpatients of Ethiopia, which was performed during a 3-month period of 2006, reported a prevalence of MRSA of 55% [@pone.0068024-Abera1]. Most of the clinical specimens were collected from surgical wounds. A retrospective study, in 3 teaching hospitals in Ivory Coast among adult and pediatric patients, reported a prevalence of 39% for MRSA [@pone.0068024-Zinzendorf1]. In Eritrea, a retrospective study, which did not mention the exact study period, reported a prevalence of 9% of MRSA among pus specimens [@pone.0068024-Naik1].

Temporal Trend in the Prevalence of the MRSA {#s3d}
--------------------------------------------

The temporal trends in the prevalence of MRSA in the high, medium and low human development index countries are presented in [Table 3](#pone-0068024-t003){ref-type="table"}. An increase in the prevalence of MRSA between earlier and later studies during the last ten years could be noted for Tunisia and Algeria, while the opposite could hold true for South Africa. In Nigeria, the data in regard were split to specific regions, while for the remaining countries there were poor relevant comparative data.

10.1371/journal.pone.0068024.t003

###### Summary table of the temporal trends in the percentage of MRSA among *S. aureus* in different countries.

![](pone.0068024.t003){#pone-0068024-t003-3}

  High Human Development Index Countries                                                                                                       
  ------------------------------------------------------------ ------------------------------------------------------------------------------- -----------------------------------------------------------
  **Mastouri,** [@pone.0068024-Mastouri1] **2006**                                  **Tunisia**; June 2002--December 2003                                            96/620 **(16)**
  **Amazian,** [@pone.0068024-Amazian1] **2006^a^**                            **Tunisia**, Algeria; March 2003--January 2004                                        42/336 **(12)**
  **Ben Saida,** [@pone.0068024-BenSaida1] **2005**                                **Tunisia**; September 2003--March 2004                                           19/147 **(13)**
  **Borg,** [@pone.0068024-Borg1] **2007^a^**                                **Tunisia**, Algeria, Egypt, Morocco; 2003 to 2005                                     105/586 **(18)**
  **Ben Ayed,** [@pone.0068024-BenAyed1] **2006**                                   **Tunisia**; January 2004--June 2005                                             57/475 **(12)**
  **Thabet,** [@pone.0068024-Thabet1] **2008**                                    **Tunisia**; January 2005--December 2006                                          174/375 **(46)**
  **Mesrati,** [@pone.0068024-Mesrati1] **2010**                                    **Tunisia**; January 2005--July 2007.                            58/143 **(41)**, CA: 22/77 (29), HA:36/66 (55)
  **Buzaid,** [@pone.0068024-Buzaid1] **2011**                                           **Libya**; April--July 2007                                                 62/200 **(31)**
  **Medium Human Development Index Countries**                                                                                                 
  **First author, year**                                                                     **Country; Period**                                **Percentage of MRSA among** ***S. aureus,*** **n/N (%)**
  **Perovic,** [@pone.0068024-Perovic1] **2006**                                **South Africa**; November 1999--October 2002                      105/449 **(23)**, CA: 21/105 (20), HA: 84/105 (80)
  **Shittu,** [@pone.0068024-Shittu1] **2006**                        **South Africa**; March--August 2001 andOctober 2002--August 2003                              61/227 **(27)**
  **Groome,** [@pone.0068024-Groome1] **2012**                                  **South Africa**; January 2005--December 2006                                        63/161 **(39)**
  **Brink,** [@pone.0068024-Brink1] **2007**                                      **South Africa**; January 2006--June 2006                                         226/629 **(36)**
  **van Rensburg,** [@pone.0068024-vanRensburg1] **2012**                          **South Africa**; July 2007--June 2011                                         3298/13.746 **(24)**
  **Amazian,** [@pone.0068024-Amazian1] **2006^a^**                            **Algeria**, Tunisia; March 2003--January 2004                                        72/203 **(35)**
  **Borg,** [@pone.0068024-Borg1] **2007^a^**                             **Algeria**, Egypt, Morocco MC (Tunisia MC);2003 to 2005                                  256/569 **(45)**
  **Antri,** [@pone.0068024-Antri2] **2011**                                      **Algeria**; April 2006 to December 2007                          99/221 **(45)**, CA: 34/84 (40), HA: 65/137 (47)
  **Rebiahi,** [@pone.0068024-Rebiahi1] **2011**                                      **Algeria**; April 2007--May 2009                                             165/220 **(75)**
  **Wood,** [@pone.0068024-Wood1] **2009**                                                **Botswana**; 2000--2007                                                  239/538 **(44)**
  **Truong,** [@pone.0068024-Truong1] **2011**                                            **Botswana**; 2000--2007                                                  194/857 **(23)**
  **Borg,** [@pone.0068024-Borg1] **2007^a^**                             Algeria, Egypt, **Morocco** MC (Tunisia MC);2003 to 2005                                   88/465 **(19)**
  **Elhamzaoui,** [@pone.0068024-Elhamzaoui1] **2009**                               **Morocco**; March 2006--March 2008                                             89/461 **(19)**
  **Ashour,** [@pone.0068024-Ashour1] **2007**                                                  **Egypt**; NR                                                       114/140 **(82)**
  **Borg,** [@pone.0068024-Borg1] **2007^a^**                             Algeria, **Egypt**, Morocco MC (Tunisia MC);2003 to 2005                                  290/557 **(52)**
  **Low human Development Index Countries**                                                                                                    
  **First author, year**                                                                     **Country; Period**                                **Percentage of MRSA among** ***S. aureus,*** **n/N (%)**
  **Adesida,** [@pone.0068024-Adesida1] **2005**                                   **Nigeria NC**; August 1998--June 2002                                            26/276 **(9)**
  **Taiwo,** [@pone.0068024-Taiwo1] **2005**                                       **Nigeria SW**; January--December 2001                                            45/141 **(32)**
  **Ghebremedhin,** [@pone.0068024-Ghebremedhin1] **2009**                               **Nigeria SW**; 2006--2007                                  70/346 **(20)**, CA: 33/70 (47), HA: 37/70 (53)
  **Fayomi,** [@pone.0068024-Fayomi1] **2011**                                     **Nigeria SW**; January--December 2009                                            49/158 **(31)**
  **Nwankwo,** [@pone.0068024-Nwankwo1] **2011**                                   **Nigeria NW**; January--December 2009                                            16/150 **(11)**
  **Terry Alli,** [@pone.0068024-TerryAlli1] **2012**                                        **Nigeria SW**; NR                                       48/116 **(41)**, CA: 3/48 (7), HA: 45/48 (93)
  **Ghamba,** [@pone.0068024-Ghamba1] **2012**                                               **Nigeria NE**; NR                                      42/148 **(28)**, CA: 18/42 (43), HA: 24/42 (57)
  **Randrianirina,** [@pone.0068024-Randrianirina1] **2007**                     **Madagascar**; January 2001--December 2005                          36/574 **(6)**, CA: 33/506 (7), HA: 3/68 (4)
  **Breurec,** [@pone.0068024-Breurec1] **2010**                **Madagascar**, **Niger**, **Senegal**, **Cameroon**;January 2007--March 2008                        86/542 **(16)**
  **Abera,** [@pone.0068024-Abera1] **2008**                                           **Ethiopia**; April--June 2006                                                89/162 **(55)**
  **Zinzendorf,** [@pone.0068024-Zinzendorf1] **2008**                                       **Ivory Coast**; NR                                                     70/180 **(39)**
  **Mshana,** [@pone.0068024-Mshana1] **2009**                                         **Tanzania**; April--July 2008                                                26/160 **(16)**
  **Naik,** [@pone.0068024-Naik1] **2009**                                                     **Eritrea**; NR                                                       26/278 **(9)**

MRSA: Methicillin-resistant *S. aureus*; CA: community-acquired; HA: hospital-acquired; MC: multicenter; NC: north-central; SW: south-west; NW: north-west; NE: north-east; NR: not reported

Community- and Hospital-acquired MRSA {#s3e}
-------------------------------------

Data on the prevalence of MRSA among community or hospital acquired *S. aureus* was reported in 4 studies [@pone.0068024-Antri2], [@pone.0068024-Mesrati1], [@pone.0068024-Perovic1], [@pone.0068024-Randrianirina1]. In 2 of these studies, the prevalence of MRSA was lower in the community-acquired *S. aureus,* while in the remaining two studies no significant differences could be observed, although in one of them the number of hospital-acquired isolates is rather low.

Susceptibility of MRSA to Various Antibiotics {#s3f}
---------------------------------------------

Detailed data on the susceptibility of the MRSA isolates collected in each of the included studies to the various antibiotics tested are presented in [Table 4](#pone-0068024-t004){ref-type="table"}. Considering all of the included studies together, the susceptibility of MRSA isolates in Africa to various antibiotics varied as follows: rifampicin 22%--100%, gentamicin 0--100%, vancomycin 82--100%, ofloxacin 40--100%, ciprofloxacin 25--100%, chloramphenicol 0--100%, cotrimoxazole 0--100%, erythromycin 0--100%, fusidic acid 33--100%, tetracycline 0--100%, clindamycin 18--100%, teicoplanin 93--100%, fosfomycin 84--99% and linezolid 85--100%. The relatively high number of MRSA isolates that were reported as non-susceptible to glycopeptides or linezolid in some studies should be interpreted with caution. In two of these studies, the susceptibility to vancomycin was determined with the disk diffusion method or with an automated system, which are not considered robust in this regard. None of these studies assessed for the presence of any of the vancomycin resistance genes.

10.1371/journal.pone.0068024.t004

###### Susceptibility to different antibiotics of MRSA isolates collected in African countries of high, medium, and low human development index.

![](pone.0068024.t004){#pone-0068024-t004-4}

  HIGH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  ------------------ -------------------------------------------------- ------------------------------------------------------ ---------------------- ------------------------------ ----------------------------- ------------------------------------------ ----------------------------- --------- ----------------------------- ------------------------------ --------------------------- ---------- ------------------------- ----------------------------- ----------------------------- ---------- ---------- --------- -----------------------------------------
                                                                                                                                                                **n (%)**                                                                                                                                                                                                                                                                                                                                                       
  **Libya**               **Buzaid, 2011** [@pone.0068024-Brink1]                        **April--July 2007**                            62                                                                         51 (82)[a](#nt106){ref-type="table-fn"}                                  41 (66)             38 (61)                                                     33 (53)            36 (58)                                                                                                                         
  **Tunisia**            **Mastouri, 2006** [@pone.0068024-Groome1]                  **June 2002--December 2003**                        96                       94(98)                        79(82)                             95 (99)^C^                            57 (59)                                 93 (97)                       84 (87)                       49 (51)            39 (41)            33 (34)                                                   94 (98)             89 (93)     2 (2)              
                        **Ben Saida, 2005** [@pone.0068024-BenAyed1]                **September 2003--March 2004**                       19                       12(63)                         0 (0)                                                                   14 (74)                                                               14 (74)                       11 (58)            18 (95)            3 (16)                                                                        16 (84)                        
                        **Mesrati, 2010** [@pone.0068024-Mastouri1]                  **January 2005--July 2007**                PVL-CA: 9PVL- HA: 12   PVL-CA9 (100)PVL- HA12 (100)   PVL-CA9 (100)PVL-HA12 (100)         PVL-CA9 (100) PVL-HA12 (100)         PVL-CA9 (100) PVL-HA11 (92)             PVL-CA9 (100)PVL-HA12 (100)   PVL-CA9 (100) PVL-HA12 (100)   PVL-CA6 (67) PVL-HA7 (58)              PVL-CA0 (0)PVL-HA4 (33)   PVL-CA9 (100) PVL-HA11 (92)   PVL-CA9 (100)PVL-HA12 (100)                                  
  **MEDIUM**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  **COUNTRY**                            **AUTHOR**                                           **PERIOD**                                                         **RIF**                        **GEN**                             **VAN**                              **OFX**             **CIP**             **CLH**                       **SXT**                       **ERY**             **FA**            **TET**                     **CLI**                       **TEC**             **FOF**    **GISA**   **AMK**                   **LZD**
  **South Africa**       **Shittu, 2006** [@pone.0068024-Rebiahi1]       **March--August 2001 and October 2002--August 2003**            61                      16 (26)                         2 (3)                              61 (100)                             50 (82)                                 51 (84)                        9 (15)                       11 (18)            61 (100)           6 (10)                      11 (18)                      61 (100)                                            
                       **Groome, 2012** [@pone.0068024-Ghebremedhin1]              **January 2005--December 2006**                                       Children with HIV: (22)                                                                                                             \>(60)                                     Children with HIV: (0)                                   \>(60)                                                                                                                \>(60)   
                          **Brink, 2007** [@pone.0068024-Breurec1]                      **January--June 2006**                          629                      560 (89)                      554 (88)                            629 (100)                                                                                                   447 (71)                                         610 (97)                                                                    629 (100)                                                           629 (100)
                       **van Rensburg, 2012** [@pone.0068024-Truong1]                  **July 2007--June 2011**                         3298                    1866 (57)                                                                                                                                                                                                                                                                                                                                                       
  **Algeria**         **Rebiahi, 2011** [@pone.0068024-Randrianirina1]                 **April 2007--May 2009**                         165                                                    115 (70)             162 (98)[d](#nt109){ref-type="table-fn"}                                                                                                                 73 (44)                                                          145 (88)                                           154 (93)                       
  **Morocco**           **Elhamzaoui, 2009** [@pone.0068024-Buzaid1]                  **March 2006--March 2008**                         89                      62 (70)                        40 (45)                             89 (100)                             36 (40)                                                               42 (47)                       36 (40)            29 (33)                                                                      83 (93)             84 (94)                        
  **Egypt**               **Ashour, 2007** [@pone.0068024-Antri2]                               **NR**                                  114                                                                         96 (84)[b](#nt107){ref-type="table-fn"}                                                                                                                                                                                                                                                                      97 (85)[b](#nt107){ref-type="table-fn"}

  **LOW**                                                                                                                                                                                                                                                                                                                                                   
  ------------------------------------------ -------------------------------------------------- --------------------------------- ---- ----------------- ------------------ ------------------ --------- ------------------ --------- --------------- ------------------ ------------------ ------------------ --------- ------------------ --------- -- -- ------------------
  **Nigeria**                                     **Taiwo, 2005** [@pone.0068024-Shittu1]          **January--December 2001**      45                                            45 (100)                                                                                                                                                                   
                                               **Ghebremedhin, 2009** [@pone.0068024-Ghamba1]            **2006--2007**            33   CA-MRSA33 (100)   CA-MRSA 33 (100)   CA-MRSA 33 (100)             CA-MRSA 33 (100)             CA-MRSA 1 (3)   CA-MRSA 33 (100)   CA-MRSA 33 (100)   CA-MRSA 33 (100)             CA-MRSA 33 (100)                   CA-MRSA 33 (100)
                                                  **Nwankwo, 2011** [@pone.0068024-Naik1]          **January--December 2009**      16                          0 (0)             16 (100)       11 (69)        9 (56)         0 (0)        0 (0)            0 (0)                                 0 (0)                                                     
                                                **Fayomi, 2011** [@pone.0068024-Elhamzaoui1]       **January--December 2009**      49                         12 (24)            49 (100)                     43 (88)                      4 (8)           15 (31)                                              37 (76)                                     
                                                  **Ghamba, 2012** [@pone.0068024-Fayomi1]                   **NR**                42                         38 (90)                           33 (79)       37 (88)        17 (40)                       21 (50)                                                                                          
  **Tanzania**                                   **Mshana, 2009** [@pone.0068024-Mesrati1]            **April--July 2008**         26                                            26 (100)                     15 (58)        17 (65)       2 (8)            8 (31)                                9 (35)        9 (35)                                      
  **Madagascar**                              **Randrianirina, 2007** [@pone.0068024-Perovic1]   **January 2001--December 2005**   36       31 (86)           32 (89)            36 (100)                     31 (86)        28 (78)      22 (61)          24 (67)            29 (81)             9 (25)                      36 (100)       35 (97)        
  **Madagascar, Niger, Senegal, Cameroon**        **Breurec, 2010** [@pone.0068024-Borg1]         **January 2007--March 2008**     76       47 (62)           38 (50)                                                                     21 (28)          41 (54)            64 (84)             9 (12)                                     75 (99)        
  **Ethiopia**                                    **Abera, 2008** [@pone.0068024-Nations1]            **April--June 2006**         89                         26 (29)            89 (100)                     22 (25)                                      23 (26)                                9 (10)                                                    
  **Eritrea**                                      **Naik, 2009** [@pone.0068024-Mshana1]                    **NR**                26                         14 (54)                                         24 (92)        19 (73)      20 (77)          19 (73)                                3 (12)                                                    

Vancomycin susceptibility was determined with a disk diffusion test.

Vancomycin and linezolid susceptibility was determined with automated system testing.

1 Isolate had a vancomycin minimum inhibitory concentration of 6 mg/l determined with the E-test method.

3 Isolates had vancomycin minimum inhibitory concentrations between 16 and 128 mg/L determined with the agar dilution method.

ERY: erythromycin; LIN: lincosamide; TET: tetracycline; RIF: rifampicin; SXT: trimethoprim-sulfamethoxazole; CLH: chloramphenicol; GEN: gentamicin; OFX: ofloxacin; CIP: ciprofloxacin; VAN: vancomycin; TEC: teicoplanin; FA: fusidic acid; FOF: fosfomycin; LZD: linezolid; AMK: amikacin; GISA: glycopeptide intermediate S. aureus

Discussion {#s4}
==========

The available evidence regarding the prevalence of methicillin resistance among *S. aureus* isolates ("prevalence of MRSA") collected in the African countries in different relevant studies yields variable findings, making the extrapolation of definitive relevant conclusions rather difficult. Certainly though, MRSA poses a visible threat in many African countries. The spread of MRSA in the African region can be worrisome, since there might be relatively limited availability of modern antibiotics effective against hospital-associated MRSA, like linezolid and daptomycin, in most of this part of the world. Furthermore, the implementation of infection control measures and the wide spread of HIV infection and tuberculosis, particularly in the sub-Saharan area, amplify the difficulty of dealing with the MRSA epidemic in Africa.

In an attempt to summarize the data evaluated in this review, we observe that in most of the high and medium human development index countries analyzed, the prevalence of MRSA gradually rose during the first years of the new millennium. The most pronounced increase was observed in Tunisia, with an increase to 41--46% after 2005, compared with a prevalence of 12%--18% in the years before. Yet, in South Africa, the prevalence of MRSA decreased from 36% in 2006 to 24% during 2007--2011, probably due to the implementation of effective infection control policies. In Botswana, the prevalence of MRSA varied between 23% and 44% for the period of 2000--2007, in 2 relevant studies. In Algeria and Egypt, according to a multicenter study, the prevalence of MRSA between 2003--2005 was 45% and 52%, respectively. Morocco is the only country where a low prevalence of MRSA seems to have been stabilized during 2003--2008. However, for most of the countries evaluated, the data for the prevalence of MRSA in different calendar years come from different studies, while the majority of these studies are single-centered. There are therefore many potential differences that should be taken into consideration, such as the country regions of reference, the type of the patient population examined, and the microbiological and sampling methods used.

Among the low human development index countries, Madagascar, Senegal, Cameroon, Niger, Eritrea and Tanzania have sustainably had a low prevalence of MRSA, varying from 6% to 16%, during 2001--2009 (according to data derived from individual studies). Moremi et al, and Blomberg et al, report similar results regarding the prevalence of MRSA in Tanzania [@pone.0068024-Blomberg1], [@pone.0068024-Moremi1]. This could hypothetically be attributed to underutilization of antibiotics in the poorer compared with the wealthier countries, leading to a comparatively lower selection pressure for MRSA [@pone.0068024-Randrianirina1]. On the other hand, in Nigeria the prevalence of MRSA appears to be different in the northern compared with the southern part of the country. For the northern part of Nigeria, the prevalence of MRSA varied from 9% in north-central to 28% in north-east, while in the south-west part of the country it was between 20% and 41%. To notice, Nigeria is geophysically divided in the northern part with the savanna and the Sahel steppe and in a southern part where dense vegetation exists. In Ethiopia and in the Ivory Coast, the prevalence of MRSA was 55% and 39%, respectively (data from individual studies).

With cautious estimates, where specific relevant data were available, it seems that the majority of the MRSA isolates were hospital-acquired for most of the included studies. This finding does not exclude the possibility that there is a considerable reservoir of community-acquired MRSA in Africa. It could be attributed to the fact that hospital-acquired isolates were more easily recorded in the included studies.

The susceptibility of MRSA to various antibiotics varied among the included studies. This can represent between studies differences in the type of the studied population; for example some studies included hospitalized cancer patients or patients with HIV infection. The observed differences in antibiotic susceptibility of MRSA in Africa could mainly be attributed to the prevalent use of certain antibiotics in some countries, either due to availability and cost-effectiveness issues or due to administration of antibiotics for other illnesses such as the use of rifampicin for treating tuberculosis. In studies that included many patients previously exposed to antibiotics, it is likely that MRSA isolates had been selected. Conversely, in a study evaluating the characteristics of *S. aureus* isolates collected from remote Gabonese Babongo Pygmies, none of the 34 isolates was resistant to methicillin, while 61,8% of the isolates remained susceptible to penicillin [@pone.0068024-Schaumburg1].

The prevalence of MRSA in Africa during the last decade, as evidenced in this review, appears to be higher compared with that before 2000, at least for certain regions [@pone.0068024-Kesah1]. In the great majority of the studies included in this review the prevalence of MRSA was either between 25% and 50%, or less than 25%. These estimates must be compared with those from other parts of the world. Specifically, in Asian countries the overall prevalence of MRSA reaches 39% [@pone.0068024-Song1]. In European countries it varies between \<1% in Iceland, Belgium, Netherlands and \>50% in Portugal and Romania according to ECDC estimates for 2011. Regarding the Mediterranean European countries, the prevalence of MRSA varies from 25%--50% in Italy, Greece, Cyprus, Turkey to 59% in Malta and 56% in Israel [@pone.0068024-The1]. Likewise, in the northern countries of Africa drenched by the Mediterranean sea, the prevalence of MRSA varies from 31% in Libya and 45% in Algeria and Tunisia to 52% in Egypt, with Morocco (the western of these countries) being the only one exhibiting a prevalence of 19%. Regarding the USA, the prevalence of MRSA appears to have been declining from 2005 through 2010, with a 51% estimate in 2009 [@pone.0068024-Landrum1].

Our approach to systematically evaluate the published literature on the prevalence of MRSA in Africa should be viewed in light of some potential limitations. As it is common for this type of reviews, we have included studies done in various settings using different methodologies regarding the patient selection criteria and the microbiological methods. Differences in the methods used can influence the findings on the prevalence of methicillin resistance among the *S. aureus* isolates. The great majority of the studies relied on phenotypic rather than molecular tests for the detection of MRSA. If molecular methods are used for confirmation of the MRSA isolates, the percentage of methicillin-resistance can be expected to be lower. Moreover, some studies used the oxacillin disk diffusion test for detecting MRSA which is considered less accurate than the cefoxitin disk diffusion test in this regard. The type of agar used can also influence the above findings.

We also set a pre-specified criterion to include only those studies that reported on at least 100 *S. aureus* isolates from patients with an infection, so as to select those studies that could provide more information that could be clinically relevant. Inevitably, some studies with a methodology of higher quality were not included. For example, a study in Gabon evaluated the molecular diversity and the virulence factors of prospectively collected *S. aureus* isolates between 2008 and 2010 [@pone.0068024-Schaumburg2]. Differences were observed between the isolates from asymptomatic carriers and those from patients with an infection. The percentage of methicillin resistance was 3.7% in the 163 isolates from carriers and 11,1% in the 44 isolates from patients with an infection. Another study examined the molecular and resistance characteristics of staphylococcal clinical isolates collected in 8 hospitals in Nigeria in 2010 [@pone.0068024-Shittu2]. The percentage of methicillin resistance (confirmed with detection of the *mecA* gene) in 51 *S. aureus* isolates was 29,4%. Differences in the clonal characteristics of MRSA were noted between North-East and South-West Nigeria.

In conclusion, the greatest amount of data for the prevalence of methicillin resistance in clinical *S. aureus* isolates over the last decade in Africa derives from the countries in the Mediterranean basin, South Africa, and Nigeria. According to this data, as well as data contributed by other countries, the burden of MRSA in Africa is not negligible. The prevalence of MRSA was at the level of 25--50% for many countries, while it was lower than 25% for some other countries. Regional differences in antibiotic availability and consumption or in the spread of HIV and tuberculosis could account for differences in MRSA prevalence between sub-Saharan countries. No decreasing trend in the prevalence of MRSA in individual countries over the study period could be noted, except possibly for South Africa. The spread of MRSA in Africa must be taken into consideration in the global battle against antimicrobial resistance.
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